Arrowhead Pharma rises after genetic disorder drug gets US FDA nod

Arrowhead Pharmaceuticals

18/11/2025 17:20

** Shares of Arrowhead Pharmaceuticals ARWR.O rise 3.19% to $41.49

** U.S. FDA approves ARWR's drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's website showed

** In a 75-patient late-stage study, the drug branded as Redemplo, reduced triglycerides, a key hallmark of the disease, by 80% and cut the risk of pancreatitis by 83% versus placebo in patients with a hereditary condition known as Familial chylomicronemia syndrome

** The condition is a rare inherited disorder that prevents the body from properly breaking down fats, leading to extremely high levels of triglycerides in the blood

** Including session's move, stock up ~115% YTD

 (Reporting by Siddhi Mahatole and Sahil Pandey)

 ((siddhi.mahatole@thomsonreuters.com))